Literature DB >> 22948975

The dynamics of DNA methylation in schizophrenia and related psychiatric disorders.

Dennis R Grayson1, Alessandro Guidotti.   

Abstract

Major psychiatric disorders such as schizophrenia (SZ) and bipolar disorder (BP) with psychosis (BP+) express a complex symptomatology characterized by positive symptoms, negative symptoms, and cognitive impairment. Postmortem studies of human SZ and BP+ brains show considerable alterations in the transcriptome of a variety of cortical structures, including multiple mRNAs that are downregulated in both inhibitory GABAergic and excitatory pyramidal neurons compared with non-psychiatric subjects (NPS). Several reports show increased expression of DNA methyltransferases in telencephalic GABAergic neurons. Accumulating evidence suggests a critical role for altered DNA methylation processes in the pathogenesis of SZ and related psychiatric disorders. The establishment and maintenance of CpG site methylation is essential during central nervous system differentiation and this methylation has been implicated in synaptic plasticity, learning, and memory. Atypical hypermethylation of candidate gene promoters expressed in GABAergic neurons is associated with transcriptional downregulation of the corresponding mRNAs, including glutamic acid decarboxylase 67 (GAD67) and reelin (RELN). Recent reports indicate that the methylation status of promoter proximal CpG dinucleotides is in a dynamic balance between DNA methylation and DNA hydroxymethylation. Hydroxymethylation and subsequent DNA demethylation is more complex and involves additional proteins downstream of 5-hydroxymethylcytosine, including members of the base excision repair (BER) pathway. Recent advances in our understanding of altered CpG methylation, hydroxymethylation, and active DNA demethylation provide a framework for the identification of new targets, which may be exploited for the pharmacological intervention of the psychosis associated with SZ and possibly BP+.

Entities:  

Mesh:

Year:  2012        PMID: 22948975      PMCID: PMC3521968          DOI: 10.1038/npp.2012.125

Source DB:  PubMed          Journal:  Neuropsychopharmacology        ISSN: 0893-133X            Impact factor:   7.853


  304 in total

1.  Histone modification levels are predictive for gene expression.

Authors:  Rosa Karlić; Ho-Ryun Chung; Julia Lasserre; Kristian Vlahovicek; Martin Vingron
Journal:  Proc Natl Acad Sci U S A       Date:  2010-02-01       Impact factor: 11.205

2.  Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells.

Authors:  M Göttlicher; S Minucci; P Zhu; O H Krämer; A Schimpf; S Giavara; J P Sleeman; F Lo Coco; C Nervi; P G Pelicci; T Heinzel
Journal:  EMBO J       Date:  2001-12-17       Impact factor: 11.598

3.  Pharmacological profile of the alpha4beta2 nicotinic acetylcholine receptor partial agonist varenicline, an effective smoking cessation aid.

Authors:  H Rollema; L K Chambers; J W Coe; J Glowa; R S Hurst; L A Lebel; Y Lu; R S Mansbach; R J Mather; C C Rovetti; S B Sands; E Schaeffer; D W Schulz; F D Tingley; K E Williams
Journal:  Neuropharmacology       Date:  2006-12-08       Impact factor: 5.250

4.  Chromatin methylation activity of Dnmt3a and Dnmt3a/3L is guided by interaction of the ADD domain with the histone H3 tail.

Authors:  Yingying Zhang; Renata Jurkowska; Szabolcs Soeroes; Arumugam Rajavelu; Arunkumar Dhayalan; Ina Bock; Philipp Rathert; Ole Brandt; Richard Reinhardt; Wolfgang Fischle; Albert Jeltsch
Journal:  Nucleic Acids Res       Date:  2010-03-11       Impact factor: 16.971

Review 5.  GABA neurons and the mechanisms of network oscillations: implications for understanding cortical dysfunction in schizophrenia.

Authors:  Guillermo Gonzalez-Burgos; David A Lewis
Journal:  Schizophr Bull       Date:  2008-06-26       Impact factor: 9.306

Review 6.  Epigenetic mediation of environmental influences in major psychotic disorders.

Authors:  Bart P F Rutten; Jonathan Mill
Journal:  Schizophr Bull       Date:  2009-09-25       Impact factor: 9.306

Review 7.  Schizophrenia genes, gene expression, and neuropathology: on the matter of their convergence.

Authors:  P J Harrison; D R Weinberger
Journal:  Mol Psychiatry       Date:  2005-01       Impact factor: 15.992

Review 8.  The role of DNA copy number variation in schizophrenia.

Authors:  Gloria W C Tam; Richard Redon; Nigel P Carter; Seth G N Grant
Journal:  Biol Psychiatry       Date:  2009-09-12       Impact factor: 13.382

9.  Monozygotic twins exhibit numerous epigenetic differences: clues to twin discordance?

Authors:  Arturas Petronis; Irving I Gottesman; Peixiang Kan; James L Kennedy; Vincenzo S Basile; Andrew D Paterson; Violeta Popendikyte
Journal:  Schizophr Bull       Date:  2003       Impact factor: 9.306

10.  Exome sequencing supports a de novo mutational paradigm for schizophrenia.

Authors:  Bin Xu; J Louw Roos; Phillip Dexheimer; Braden Boone; Brooks Plummer; Shawn Levy; Joseph A Gogos; Maria Karayiorgou
Journal:  Nat Genet       Date:  2011-08-07       Impact factor: 38.330

View more
  104 in total

Review 1.  DNA modifications and neurological disorders.

Authors:  Yi-Lan Weng; Ran An; Jaehoon Shin; Hongjun Song; Guo-li Ming
Journal:  Neurotherapeutics       Date:  2013-10       Impact factor: 7.620

Review 2.  Interneuron epigenomes during the critical period of cortical plasticity: Implications for schizophrenia.

Authors:  Hirofumi Morishita; Marija Kundakovic; Lucy Bicks; Amanda Mitchell; Schahram Akbarian
Journal:  Neurobiol Learn Mem       Date:  2015-04-04       Impact factor: 2.877

Review 3.  Transcriptional regulation of GAD1 GABA synthesis gene in the prefrontal cortex of subjects with schizophrenia.

Authors:  Amanda C Mitchell; Yan Jiang; Cyril Peter; Schahram Akbarian
Journal:  Schizophr Res       Date:  2014-10-31       Impact factor: 4.939

Review 4.  5-Hydroxymethylcytosine: A new player in brain disorders?

Authors:  Ying Cheng; Alison Bernstein; Dahua Chen; Peng Jin
Journal:  Exp Neurol       Date:  2014-05-17       Impact factor: 5.330

5.  Epigenetic changes in leukocytes after 8 weeks of resistance exercise training.

Authors:  Joshua Denham; Francine Z Marques; Emma L Bruns; Brendan J O'Brien; Fadi J Charchar
Journal:  Eur J Appl Physiol       Date:  2016-05-07       Impact factor: 3.078

Review 6.  Altering the course of schizophrenia: progress and perspectives.

Authors:  Mark J Millan; Annie Andrieux; George Bartzokis; Kristin Cadenhead; Paola Dazzan; Paolo Fusar-Poli; Jürgen Gallinat; Jay Giedd; Dennis R Grayson; Markus Heinrichs; René Kahn; Marie-Odile Krebs; Marion Leboyer; David Lewis; Oscar Marin; Philippe Marin; Andreas Meyer-Lindenberg; Patrick McGorry; Philip McGuire; Michael J Owen; Paul Patterson; Akira Sawa; Michael Spedding; Peter Uhlhaas; Flora Vaccarino; Claes Wahlestedt; Daniel Weinberger
Journal:  Nat Rev Drug Discov       Date:  2016-03-04       Impact factor: 84.694

7.  Lithium reduces the effects of rotenone-induced complex I dysfunction on DNA methylation and hydroxymethylation in rat cortical primary neurons.

Authors:  Gustavo Scola; Helena K Kim; L Trevor Young; Mirian Salvador; Ana C Andreazza
Journal:  Psychopharmacology (Berl)       Date:  2014-04-29       Impact factor: 4.530

8.  Kinetic Analysis and Quantification of [¹¹C]Martinostat for in Vivo HDAC Imaging of the Brain.

Authors:  Hsiao-Ying Wey; Changning Wang; Frederick A Schroeder; Jean Logan; Julie C Price; Jacob M Hooker
Journal:  ACS Chem Neurosci       Date:  2015-03-25       Impact factor: 4.418

9.  Maternal immune activation induces GAD1 and GAD2 promoter remodeling in the offspring prefrontal cortex.

Authors:  Marie Anaïs Labouesse; Erbo Dong; Dennis Robert Grayson; Alessandro Guidotti; Urs Meyer
Journal:  Epigenetics       Date:  2015       Impact factor: 4.528

10.  DNA methylation and gene deletion analysis of brain metastases in melanoma patients identifies mutually exclusive molecular alterations.

Authors:  Diego M Marzese; Richard A Scolyer; Maria Roqué; Laura M Vargas-Roig; Jamie L Huynh; James S Wilmott; Rajmohan Murali; Michael E Buckland; Garni Barkhoudarian; John F Thompson; Donald L Morton; Daniel F Kelly; Dave S B Hoon
Journal:  Neuro Oncol       Date:  2014-06-26       Impact factor: 12.300

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.